Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk
  • Geographic Atrophy

Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk

Ophthalmology 360

Key Takeaways

  1. Vision loss progressed over time in patients with geographic atrophy, with the proportion of patients having visual acuity worse than 20/100 increasing from 12.8% at diagnosis to 24.3% by year 2.
  2. Patients with subfoveal involvement experienced faster vision decline, reaching visual acuity worse than 20/40 in a median of 2.2 years versus 3.8 years for those without subfoveal involvement.

Geographic atrophy (GA) was associated with progressive vision loss, higher healthcare costs, and a potential increase in the risk of falls and fractures, according to a study from the American Academy of Ophthalmology IRIS Registry.

Researchers evaluated 63,616 patients aged 50 years or older who had valid visual acuity (VA) measurements before and after diagnosis. The proportion of patients with visual acuity below 20/100 increased from 12.8% at diagnosis to 24.3% by the second year.

The median time to reach visual acuity worse than 20/40 was 3 years. Patients with subfoveal involvement reached the visual acuity threshold of worse than 20/40 sooner than those without subfoveal involvement, with median times of 2.2 and 3.8 years, respectively.

A claims-linked analysis included 5,827 patients from a homogeneous cohort designed to control for other eye diseases and procedures that could affect vision or healthcare utilization. By year 2, visual impairment was associated with more than a 26% increase in total medical care costs.

Moderate to severe visual impairment was also suggestive of an increased risk of falls and fractures.

Reference
Borkar D, Arkin-Leydig K, Toth J, et al. Vision, Medical Cost, and Risk of Falls and Fractures in Geographic Atrophy: An American Academy of Ophthalmology IRIS Registry Analysis. J Vitreoretin Dis. 2026;24741264261448421. doi: 10.1177/24741264261448421. Epub ahead of print. PMID: 42239975; PMCID: PMC13226300.

Share

Related Content

  • Geographic Atrophy

Spotlight on IZERVAY®

  • Geographic Atrophy

Two-year GATHER2 data show sustained GA growth reduction with avacincaptad pegol

  • Conference Roundup

Floretina 2025: study shows reduced treatment burden with EYP-1901 for neovascular AMD

3 Mins Watch
  • Geographic Atrophy

Over half of patients with dry AMD developed advanced disease in long-term analysis

  • Geographic Atrophy

Monthly avacincaptad pegol reduces geographic atrophy lesion growth for up to 3.5 years

  • Anterior Segment

Deep learning algorithm performs similarly to manual grading of GA on an OCT data set

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon